Tukysa Europska Unija - hrvatski - EMA (European Medicines Agency)

tukysa

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastična sredstva - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Lumeblue (previously known as Methylthioninium chloride Cosmo) Europska Unija - hrvatski - EMA (European Medicines Agency)

lumeblue (previously known as methylthioninium chloride cosmo)

alfasigma s.p.a. - metiltioninijev klorid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Elzonris Europska Unija - hrvatski - EMA (European Medicines Agency)

elzonris

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastična sredstva - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Zejula Europska Unija - hrvatski - EMA (European Medicines Agency)

zejula

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastična sredstva - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Bondronat Europska Unija - hrvatski - EMA (European Medicines Agency)

bondronat

atnahs pharma netherlands b.v. - ibandroninska kiselina - hypercalcemia; breast neoplasms; neoplasm metastasis; fractures, bone - lijekovi za liječenje bolesti kostiju - Бондронат je indiciran za:prevenciju skeletnih događaja (patološke frakture, komplikacije kostiju, zahtijevaju radijacijske terapije ili operacije) kod bolesnika s rakom dojke i koštanih metastaza;liječenje tumor-induced гиперкальциемии sa ili bez metastaza.

Ibandronic Acid Sandoz Europska Unija - hrvatski - EMA (European Medicines Agency)

ibandronic acid sandoz

sandoz gmbh - ibandroninska kiselina - breast neoplasms; neoplasm metastasis; fractures, bone - pripravci za liječenje bolesti kostiju, bisfosfonatima - ibandronatna kiselina sandoz je indiciran za sprječavanje koštanih poremećaja (patološki prijelomi, komplikacije na kostima koje zahtijevaju radioterapiju ili operaciju) u bolesnika s dojke rak i koštanim metastazama.

Ibandronic Acid Teva Europska Unija - hrvatski - EMA (European Medicines Agency)

ibandronic acid teva

teva pharma b.v. - ibandroninska kiselina - breast neoplasms; neoplasm metastasis; fractures, bone; osteoporosis, postmenopausal - lijekovi za liječenje bolesti kostiju - Ибандронатом 50mgibandronic kiseline tewa indiciran za prevenciju skeletnih događaja (patološke frakture, komplikacije kostiju, zahtijevaju radijacijske terapije ili operacije) kod bolesnika s rakom dojke i метастазами u kosti . ibandronic acid 150mgtreatment of osteoporosis in postmenopausal women at increased risk of fracture. smanjenje rizika od prijeloma kralježaka je pokazao učinkovitost na prijeloma vrata bedrene kosti nije instaliran.